Agenus Inc. (AGEN)

3.57
0.10 2.70
NASDAQ : Health Technology
Prev Close 3.67
Open 3.66
Day Low/High 3.46 / 3.66
52 Wk Low/High 1.54 / 6.19
Volume 1.49M
Avg Volume 1.82M
Exchange NASDAQ
Shares Outstanding 119.98M
Market Cap 440.34M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.

First Week Of January 2019 Options Trading For Agenus (AGEN)

First Week Of January 2019 Options Trading For Agenus (AGEN)

Investors in Agenus Inc saw new options begin trading this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new January 2019 contracts and identified the following put contract of particular interest.

Agenus To Present At The 2018 Jefferies London Healthcare Conference

Agenus To Present At The 2018 Jefferies London Healthcare Conference

LEXINGTON, Mass., Nov.

Agenus To Present Data On Neoantigen Vaccines And Anti-CD137 Antibody At SITC 2018

Agenus To Present Data On Neoantigen Vaccines And Anti-CD137 Antibody At SITC 2018

- AutoSynVax™ (ASV™), AGEN2003 clinical trials data

Agenus Reports Third Quarter 2018 Financial Results And Provides Corporate Update

Agenus Reports Third Quarter 2018 Financial Results And Provides Corporate Update

- 130 patients treated with Agenus' PD-1 & CTLA-4; clinical benefit >63% treated

Agenus Presents Clinical Data On Its PD-1 & CTLA-4 At ESMO 2018

Agenus Presents Clinical Data On Its PD-1 & CTLA-4 At ESMO 2018

- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses

Agenus To Present Data On Proprietary CTLA-4 & PD-1 Antibodies At ESMO 2018

Agenus To Present Data On Proprietary CTLA-4 & PD-1 Antibodies At ESMO 2018

- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer

Interesting AGEN Put And Call Options For May 2019

Interesting AGEN Put And Call Options For May 2019

Investors in Agenus Inc saw new options become available this week, for the May 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

LEXINGTON, Mass., Sept.

Agenus Receives Milestone Payment From Incyte

Agenus Receives Milestone Payment From Incyte

- Payment of $5M received for initiation of Phase 1 trial of LAG-3 antibody

Agenus Receives Second Milestone Payment From Merck

Agenus Receives Second Milestone Payment From Merck

- Payment of $4M received for initiation of phase 1 trial

Agenus Reports Second Quarter 2018 Financial Results And Provides Corporate Update

Agenus Reports Second Quarter 2018 Financial Results And Provides Corporate Update

- Cash milestones earned from Merck & Incyte

Interesting AGEN Call Options For September 21st

Interesting AGEN Call Options For September 21st

Investors in Agenus Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new September 21st contracts and identified the following call contract of particular interest.

First Week Of AGEN February 2019 Options Trading

First Week Of AGEN February 2019 Options Trading

Investors in Agenus Inc saw new options begin trading this week, for the February 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting AGEN Call Options For July 20th

Investors in Agenus Inc saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new July 20th contracts and identified the following call contract of particular interest.

June 15th Options Now Available For Agenus (AGEN)

June 15th Options Now Available For Agenus (AGEN)

Investors in Agenus Inc saw new options become available today, for the June 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 114 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of AGEN March 16th Options Trading

First Week of AGEN March 16th Options Trading

Investors in Agenus Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new March 16th contracts and identified the following call contract of particular interest.

Interesting AGEN Put And Call Options For December 15th

Interesting AGEN Put And Call Options For December 15th

Investors in Agenus Inc saw new options begin trading this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new December 15th contracts and identified one put and one call contract of particular interest.

It's All About the Earnings: Cramer's 'Mad Money' Recap (Monday 10/23/17)

It's All About the Earnings: Cramer's 'Mad Money' Recap (Monday 10/23/17)

A not-so-hot-day for the market, says Jim Cramer, but it pays to be optimistic about the stocks of companies that deliver good earnings numbers.

AGEN September 15th Options Begin Trading

AGEN September 15th Options Begin Trading

Investors in Agenus Inc saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new September 15th contracts and identified the following put contract of particular interest.

Market's Trading Range Loosens Up

Market's Trading Range Loosens Up

Netflix is the star as S&P, Nasdaq set records.

TheStreet Quant Rating: D- (Sell)